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Abstract
Background: Despite increasing investment in suicide prevention, Australian suicide rates have increased steadily in
the past decade. In response to growing evidence for multicomponent intervention models for reducing suicide,
the LifeSpan model has been developed as the first multicomponent, evidence-based, system-wide approach to
suicide prevention in Australia. The LifeSpan model consists of nine evidence-based strategies. These include
indicated, selective and universal interventions which are delivered simultaneously to community and healthcare
systems over a 2-year implementation period. This study will evaluate the effectiveness of the LifeSpan model in
reducing suicide attempts and suicide deaths in four geographically defined regions in New South Wales, Australia.
Methods: We outline the protocol for a stepped-wedge, cluster randomized controlled trial. Following a 6-month
transition phase, the trial sites will move to the 2-year active implementation phase in 4-monthly intervals with
evaluation extending a minimum of 24 months after establishment of the full active period. Analysis will be
undertaken of the change attributable to the invention across the four sites. The primary outcome for the study is
the rate of attempted suicide in the regions involved. Rate of suicide deaths within each site is a secondary
outcome.
Discussion: If proven effective, the LifeSpan model for suicide prevention could be more widely delivered in Australian
communities, providing a valuable new approach to tackle rising suicide rates. LifeSpan has the potential to significantly
contribute to the mental health of Australians by improving help-seeking for suicide, facilitating early detection, and
improving aftercare to reduce re-attempts. The findings from this research should also contribute to the evidence base
for multilevel suicide prevention programs internationally.
Trial registration: Australia New Zealand Clinical Trials Register, ID: ACTRN12617000457347. Prospectively registered on
28 March 2017. https://www.anzctr.org.au/TrialSearch.aspx#&&conditionCode=&dateOfRegistrationFrom=
&interventionDescription=&interventionCodeOperator=OR&primarySponsorType=&gender=&distance=&postcode=
&pageSize=20&ageGroup=&recruitmentCountryOperator=OR Protocol Version: 1.0, 31 May 2019.
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Background
Suicidal behavior presents a significant health burden in
terms of premature mortality and preventable disability,
with more than 3000 deaths per year in Australia [1],
compared to 1785 deaths a decade ago [1]. The national
suicide rate has increased by 13.4% over the past decade
[1]. Large population surveys indicate a similarly stable
or increasing pattern for suicide ideation and attempts
[2]. There are significant economic costs associated with
suicide (e.g., forensic and medical responding, lost prod-
uctivity), with estimates that suicide deaths alone cost
AU$1.7b annually in Australia [3]. The costs associated
with self-harm and suicide attempts are likely to increase
this amount due to substantial disability and loss of
years of healthy life, medical care costs, and secondary
distress and productivity impact caused to family mem-
bers and friends. Despite suicide prevention being a glo-
bal health priority, the problem does not seem to be
improving.
Now, more than ever, government, communities, and
organizations around the world are focused on the pre-
vention of suicide, with an increasing number of efforts
being funded to take place within, and between, coun-
tries. This commitment has led to the development and
implementation of a range of interventions aimed at the
prevention of suicidal behavior. However, based on a re-
cent review [4] not all initiatives have evidence for pre-
venting suicidal behaviors, and often, less effective
strategies, such as public awareness campaigns, may be
the most commonly implemented because they may be
least resource intensive [5]. Given the scope, severity,
and consistency of the suicide problem, it is becomingly
increasingly recognized that if an impact is to be made
at the population level, evidence-based approaches in
suicide prevention are required, and single-intervention
approaches are not sufficient. Recent research indicates
that even one suicide prevention strategy with the best
evidence, implemented in optimal conditions, is likely to
have only a small impact on suicide rates [6].
One of the more promising suicide prevention ap-
proaches in the past decade has been the development
of multicomponent models, which deliver multiple
evidence-based strategies, simultaneously, in high-risk
geographic regions. This approach has emerged in rec-
ognition that no single suicide prevention strategy
clearly stands above the others as an effective prevention
approach at either the individual or population level [4].
Multicomponent approaches typically combine a range
of preventive interventions, spanning from indicated
intervention for the highest risk individuals (e.g., people
who have attempted suicide) through to universal pre-
vention efforts that apply to the wider community (e.g.,
reducing access to means, gatekeeper training). Through
the combination of universal, selected, and indicated
interventions there is increased likelihood of reaching
those who are reluctant to seek help, improving early
identification, and improving support to high-risk indi-
viduals during critical time points for re-attempt. Grow-
ing evidence from Europe, the USA, United Kingdom,
and Japan indicates that multilevel, multimodal system
approaches that target health and community settings
are an effective way of reducing the rate of suicide, as
compared to traditional silo approaches [7, 8].
In response to the promising evidence for multilevel
interventions for reducing suicidal acts (attempts and/or
deaths), the LifeSpan model was developed in 2015 [9].
LifeSpan is a large-scale, community-wide trial for sui-
cide prevention that will be implemented in four high-
priority regions in New South Wales (NSW), the most
populous state of Australia. LifeSpan involves imple-
menting nine evidence-based strategies, simultaneously,
for a period of 2 years. Each site has its own local imple-
mentation team so that interventions, while maintaining
core features for effectiveness, may be tailored to suit
the local environment. The four sites are supported by a
central implementation team and a research team based
at the Black Dog Institute.
The LifeSpan project represents the first scientific trial
of a complex, multilevel suicide prevention approach in
Australia.
Primary aim
(i) To examine whether the LifeSpan intervention
reduces suicide attempts after implementation in
the four regions relative to rates and temporal tends
established from data covering a period from 2012
until the introduction of LifeSpan in each region
Secondary aims
(i) To examine whether the LifeSpan intervention
reduces suicide death rates in the four regions,
relative to rates and temporal tends in the pre-
intervention period
(ii) To examine change in rates of suicidal acts (both
suicide deaths and attempts) after introduction of
LifeSpan in the four regions, relative to rates and
temporal tends in the pre-intervention period
(iii)To examine the change of rates of suicidal acts in
the trial sites compared to the rest of NSW where
LifeSpan is not being implemented over the period
of data collection
Primary hypothesis
(i) That the suicide attempt rate will be lowered within
the intervention regions after the implementation of
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LifeSpan compared rates and trends established in
the pre-implementation period
Secondary hypotheses
(i) That the rate of suicidal acts will be lowered within
the intervention regions after the implementation of
LifeSpan compared with rates and trends
established in the pre-implementation period
(ii) That the LifeSpan intervention sites will achieve
greater reductions in the rate of suicidal acts in the
period after the full establishment of the program
compared to the remainder of the State (NSW) in
which LifeSpan is not being implemented
The LifeSpan research program also has other second-
ary and tertiary aims and hypotheses, including an
examination of the cost-effectiveness of the LifeSpan
model, the impact of LifeSpan on help-seeking among
the community and at-risk persons, and changes in re-
ferral and treatment practices. These aims and outcomes
will be described in separate protocols and publications
as the data for these questions will be examined in sub-
groups or different samples.
All study endpoints are reviewed and verified by a re-
search evaluation and monitoring committee.
Methods
Study design
The trial uses a community-based, pragmatic, stepped-
wedge, cluster randomized design. In this design, the
four “clusters” (i.e., trial sites) transition from the control
condition to the intervention condition at 4-month in-
tervals, until all clusters are exposed (Fig. 1). Each
cluster has an “establishment” or planning period dir-
ectly prior to moving into the “active intervention” phase
of the trial. This is a 6-month period where sites will not
be considered fully exposed to the intervention, and as
such, this period will be used in the estimation of the ef-
fect of LifeSpan. During the establishment phase, site
trial coordinators will be employed, suicide collabora-
tives involving key organizations will be established if
they do not already exist, and a local steering committee
will be created.
Once a cluster reaches the “active intervention” phase,
they have an implementation period of 2 years in which
to establish all nine strategies. By the end of this 2-year
period, all nine strategies are intended to be operating
simultaneously.
The stepped-wedge design was chosen for logistical,
political, and economic reasons. The number of clusters
required for a randomized controlled trial would have
been beyond the scope of the project budget, and it
would have been too resource intensive to intervene
simultaneously in multiple clusters in a trial of this scale.
Moreover, at the time the trial was being considered,
there was increasing suicide prevention activity across
Australia, which led to concerns about the ability to
identify control sites where new suicide prevention activ-
ity would not confound the study outcomes. Finally, the
investigators were concerned that control regions would
find it unacceptable to be allocated to the control condi-
tion rather than the intervention condition and be lim-
ited in their suicide prevention activities for over 2 years.
Participants and eligibility criteria
LifeSpan aimed to deliver interventions which were inte-
grated in a healthcare region. Regions were defined as
Fig. 1 Stepped-wedge trial design including baseline, establishment, active implementation, and data collection periods
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being one or more Local Government Areas (LGAs)
which interact meaningfully and fall within the boundar-
ies of a single Local Health District or a Primary Health
Network. Lead agencies within NSW were invited to
submit a written application as part of an Expression of
Interest (EOI) selection process. Lead agencies could be
a Local Health District, Primary Health Network, or
non-government organization, and needed to demon-
strate that they had strong relationships with other key
agencies within their region in order to deliver the
programs within the LifeSpan model. Applications were
assessed by a panel of five individuals holding senior
leadership positions in the mental health and suicide
prevention sectors, including a National Mental Health
Commissioner, the Director of the Mental Health
Australia Board, representatives from the NSW Ministry
of Health and the NSW Mental Health Commission and
NSW Aboriginal Mental Health Workforce Program.
The sites were rated against the following five key se-
lection criteria designed to demonstrate feasibility to im-
plement LifeSpan:
1. Capability and capacity of the lead agency and
partnership consortium
2. Proposed model, partnerships and project plan
3. Risk management processes
4. Community engagement and communication plan
5. Indicative budget to support implementation
In addition to the above inclusion criteria, sites needed
to be able to yield reliable outcome data on rates of sui-
cide attempts and suicide deaths. Accordingly, sites were
required to have a minimum base population of 145,000
persons to allow for sufficient statistical power to detect a
primary intervention effect. Archival data on suicide mor-
tality and non-fatal hospital admissions for intentional
self-harm were analyzed in a preceding early phase scop-
ing study [10] to allocate LGA geographies into quartiles
for suicide mortality and morbidity indicators. LGAs with
incidence rates that fell within the top quartile for suicide
mortality and/or non-fatal incidents were prioritized for
site selection in addition to the EOI inclusion criteria, to
ensure that the LifeSpan intervention would be imple-
mented in areas with greatest need for suicide prevention
efforts. The following sites were selected as a result of this
process (Table 1).
Randomization
After selecting the sites according to the inclusion criteria,
the four sites (clusters) were randomized to a start order.
Randomization was performed using the “sample” func-
tion in R, to generate a random order of numbers between
1 and 4 without replacement. Cluster randomization was
undertaken for administrative convenience, and for the
ecological validity of providing the intervention at the
community level. Randomization was carried out by a
statistician not involved in the day-to-day conduct of the
trial according to ICH Guidelines.
Study setting
The LifeSpan model is being delivered into the four distinct
geographic regions in NSW described above (Newcastle, Illa-
warra Shoalhaven, Central Coast, and Murrumbidgee). Geo-
graphically defined outcome data were built up to the LGA
level from a set of Australian Bureau of Statistics (ABS) 2016
State Suburbs Codes (SSCs). The ABS SSCs will be static for
5 years, meaning that regardless of the boundary variations
associated with LGAs during the active trial phase, suicide
incidents and delivery of the LifeSpan strategies will remain
in-scope.
Intervention
The LifeSpan intervention consists of nine evidence-
based suicide prevention strategies. These strategies in-
clude universal strategies designed to reach the entire
population (regardless of risk), selective strategies which
target subgroups of the general population that are de-
termined to be at risk for suicide and indicated strategies
for individuals who are experiencing early signs of sui-
cide crisis or behavior. The implementation of all nine
strategies within each region over the 2 years of active
intervention (Fig. 1) is managed by site coordinators in
collaboration with the LifeSpan central team and rele-
vant organizations or services, with the intention that all
are operating simultaneously within a region by the end
of Year 2. For some of the strategies, there are multiple
programs or resources that are recommended and sup-
ported by LifeSpan funding. Trial sites will be required
to implement at least one program or resource under
each of the nine strategies. The nine interventions are
described below, grouped according to universal, select-
ive, and indicated strategies.
Table 1 Trial sites selected to receive the LifeSpan intervention
Site (Local Government Areas
within scope)
Lead agency Site
start
order
“Newcastle”
(Newcastle)
Hunter New England Local
Health District
1
“Illawarra Shoalhaven”
(Wollongong, Shellharbour,
Kiama, Shoalhaven)
COORDINAIRE – the South
Eastern New South Wales
Primary Health Network
2
“Central Coast”
(Gosford, Wyong)
Central Coast Local Health
District
3
“Murrumbidgee”
(Bland, Cootamundra, Griffith,
Hay, Junee, Leeton, Tumut
Shire, Wagga Wagga, Young)
Murrumbidgee Primary Health
Network
4
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Program components
Universal prevention strategies
1. Means’ restriction activities, informed by a detailed
suicide profile for each region that identifies
hotspots and priority means
2. Training in best-practice Mindframe media report-
ing guidelines [11] for local journalists and key
media representatives
3. School-based suicide prevention programs delivered
to all students
4. Public awareness raising of suicide and health
promotion in partnership with R U OK? [12] and
delivered during national suicide prevention
awareness week
Selective prevention strategies
5. Suicide Prevention Gatekeeper training for the
whole community, using the Question, Persuade,
Refer (QPR) program [13].
6. Training for frontline responders for upskilling in
how to support individuals with suicidal ideation or
self-harming behaviors
7. Training in psychosocial treatments for suicide to
psychologists and allied health professionals, and
implementation of the Collaborative Assessment
and Management of Suicidality (CAMS) [14]
framework in relevant healthcare settings
8. Capacity building and training in suicide detection
for general practitioners (GPs) through face-to-face
training programs, and digital tools to assist with
early detection and referral
Indicated strategies
9. Establishment of aftercare services in sites where
such services do not exist, to provide support to
individuals following a suicide attempt, and
development and dissemination of best practice
guidelines for effective crisis and aftercare [15] for
emergency departments (EDs)
See Appendix for a comprehensive description of the
nine strategies.
Control condition
As part of the stepped-wedge design, each site contrib-
utes pre-intervention or “control” data. Rates suicide at-
tempts and suicide deaths and their temporal trends will
be established based on at least a decade of data from
2012, acquired retrospectively, from archival coronial
data, ambulance data, hospital separations and ED data.
Data will be acquired at a unit (patient) level, with
geocoordinates of incident location, so that suicide data
can be mapped to each of the four sites.
Outcomes
Primary outcome
The primary outcome of the study will be the rate of
treated suicide attempts in the period from full imple-
mentation of LifeSpan until March 2020. This rate will
be compared to rates and their temporal trend in the
pre-intervention period (defined in each site as the
period from July 2012 until the start of implementation).
There is currently no gold standard dataset for suicide
attempt; for this study we will identify self-harm at-
tempts using three key datasets from the Centre for
Health Record Linkage, NSW Health, which are outlined
in Table 2. Incidents to be included in the linkage will
be determined using International Classification of
Diseases Australian Modification codes for intentional
self-harm (i.e., X60-X84 (intentional self-harm), Y87.0
(sequelae of intentional self-harm)) [16]. Data will be ob-
tained for the period of 2012–2021, where possible, and
each incident case will geocoded to a specific incident
address using longitude and latitude coordinates. The in-
cident addresses will also be geocoded to a suburb using
Australian Bureau of Statistics (ABS) 2016 State Suburb
Codes (SSC) so that each case can be assigned to one of
the four respective regions. By linking these three data-
sets, duplicate incidents will be able to be removed and
the maximum number of self-harm cases identified. Nar-
rative text fields in all datasets will be reviewed to
maximize identification of suicide attempt cases. Waiver
of consent is requested for all attempt and mortality data
as data aggregation for outcome analyses means that
there is a low or negligible risk that individuals will be
identifiable.
Secondary outcomes
The secondary outcomes of the study will be changes in
the rate of suicide deaths, and changes in suicidal acts
(combined deaths and attempts) within each site at 24
months relative to the control baseline period. To assess
changes in mortality rates, unit-level mortality data (i.e.,
individual suicide cases) geocoded to trial-site geo-
graphic boundaries or to NSW will be acquired from the
National Coronial Information System (NCIS) for all
registered suicide deaths in NSW in the period 2006–
2021. The method for identifying cases and assigning
them to sites is the same as for the primary outcome. To
further examine the effects of secular trends on the pri-
mary and secondary outcomes, sensitivity analyses will
examine whether changes in suicide attempts, acts and
deaths were different in trial sites to the rest of NSW.
This analysis will assist in controlling for broader social
and economic influences on suicide rates.
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Recruitment and consent
Following the EOI selection process, successful appli-
cants were notified of their acceptance into the LifeSpan
trial. To confirm their participation in the trial, a con-
tract describing roles, responsibilities, and key perform-
ance indicators was prepared and signed by the Black
Dog Institute and the lead agency for each site.
Follow-up
Primary and secondary outcome data will be acquired
for 12 months post baseline (end of Year 1 of active
intervention) and 24 months post baseline (end of Year
2 of active intervention), though the primary point of
interest is the latter.
Data management
The LifeSpan data environment will be hosted on a
stand-alone secure server maintained by the Univer-
sity of New South Wales. Access to this secure server
is through unique staff identification accounts and
passwords. The raw data within the environment is
stored in project-specific folders related to ethical
agreements for access. These folders are protected by
an Active Directory Rights Management Service
(ADRMS) and are only accessible by individuals listed
on appropriate ethics agreements. The data team
listed on these agreements transforms the raw data
into SAS datasets, which are protected by both AD
RMS and SAS metadata security permissions. Datasets
are then made available to researchers granted access
dependent on ethical approval.
Sample size and statistical analysis
In the primary outcome analysis, changes in suicide at-
tempt presentation rates per 100,000 population will be
tested by comparing the mean annual attempt rate from
July 2012 until the implementation date (pre-implemen-
tation) with the mean annual attempt rate from the
implementation date till the end of the active implemen-
tation period (24 months post baseline), combined
across all four trial sites. To determine whether the
changes in trial-site suicide attempt rates were different
to those occurring elsewhere, sensitivity analyses will use
the suicide attempt rate for the rest of the NSW popula-
tion as a background rate. Subsequent analysis will
examine changes in treated suicide attempt rates pre
and post implementation by individual site. The treated
suicide attempt rate will be calculated per 100,000 popu-
lation using the three linked datasets described for the
primary outcome: ambulance data, ED data, and admit-
ted patient data.
To examine changes in suicide deaths, the pre- and
post-baseline rates per 100,000 will be calculated using
data from the National Coronial Information System. As
for the suicide attempt rates, the suicide death rates will
be examined for all four trial sites collectively and for
each individual site and compared with the background
suicide death rates for the remainder of the NSW popu-
lation in sensitivity analysis.
The alpha level will be set at 0.05 for all analyses.
The mean rate of treated suicide attempt presentations
in the period 2005–2013 was approximately 250 per 100,
000 per year in the four target sites, based only on
hospital admission records. We have previously calcu-
lated that the nine strategies could, cumulatively or
Table 2 Primary and secondary outcome data sources
Suicide mortality data Suicide attempt data
National Coronial Information
System (NCIS)
NSW ambulance data NSW Admitted Patient Data
Collection (APDC)
Emergency Department Data
Collection (EDDC)
Level
data to
be
acquired
at
Individual/point data Individual/point data Individual/point data per
hospital separation
Individual/point data
Years
data will
be
acquired
for
Jan 2006 – Dec 2021 Jul 2012 – Jun 2021 Jan 2007 – Jun 2021 Jan 2007 – Jun 2021
Summary
of data
The NCIS is a data-storage, re-
trieval, analysis, interpretation,
and dissemination system for
coronial information. It enables
coroners, their staff, public sec-
tor agencies, researchers, and
other agencies to access coron-
ial data to inform death- and
injury-prevention activities
Ambulance data contains a
collection of operational
information from computer-
aided dispatch (CAD), electronic
medical records (eMR), and data
documented by clinicians
through patient healthcare
records
APDC records all inpatient
separations (discharges, transfers,
and deaths) from all public,
private, psychiatric, and
repatriation hospitals in New
South Wales (NSW), as well as
public multi-purpose services,
private day-procedure centres,
and public nursing homes
The EDDC is an administrative
data collection detailing
presentations to emergency
departments at public
metropolitan hospitals in NSW.
Diagnosis coding is not by
trained clinical information
manager but by medical,
nursing, or clerical personal
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synergistically, reduce the rate of attempts by up to 30%
[6]. However, the magnitude of the effect of a multilevel
approach is likely to vary by the extent and length of im-
plementation, the reach of exposure of individuals to
multiple strategies, and the existing quality and availabil-
ity of services and initiatives within communities at
baseline. Detecting such change within one trial site
relative to another trial site, with 90% power, would re-
quire a population within each site of at least 79,000
people. As each trial site has at least 145,000 population,
we will be able to detect reductions of approximately 7%
in suicide attempt rates within each site.
Adverse events
All serious adverse, unexpected, or possibly related
events (including data breaches) will be recorded in a
case report form and will be reported to the director of
the LifeSpan trial and the principle investigator, Profes-
sor Helen Christensen. A case report will be submitted
to the relevant HREC agency/ies and the relevant data
custodian/s. The recommendations from the HREC and
data custodians will guide whether the study can con-
tinue or be stopped.
Discussion
This study will use a stepped-wedge, cluster randomized
controlled trial design to investigate the impact of the
LifeSpan multilevel, multimodal intervention on rates of
suicide attempt and suicide death in four geographic re-
gions in NSW. If the program proves efficacious, the
LifeSpan model can be implemented in additional high-
priority regions, nationally.
This study has a number of limitations which are likely
to have an impact on the stated outcomes. Firstly, the
scope and intensity of some of the interventions may be
difficult to implement within 2 years, particularly
resource-intensive interventions (e.g., aftercare services)
for which regions have not yet secured funding to estab-
lish. Achieving reductions in suicide deaths and attempts
will be strongly influenced by our ability to achieve suffi-
cient dose, reach, and sustainability in our implementa-
tion efforts. Secondly, it is also likely going to be difficult
to monitor fidelity of implementation within a trial of
this scale, which is problematic insomuch that the fidel-
ity with which the strategies are implemented is likely to
impact effectiveness. Thirdly, the reliance on secondary
administrative data for the evaluation may be problem-
atic, as there are data lags in coronial data as well as
reporting biases in administrative data which may affect
the accuracy of the primary and secondary outcomes.
The fourth limitation is raised in relation to the length
of the trial, only being 2.5 years’ duration, as this is un-
likely to be sufficient time to embed the strategies locally
to achieve population-level impact. The length of the
trial also raises the risk of dropout of key staff, which
may impact how the interventions are delivered on the
ground. Relatedly, the interventions (e.g., school-based
programs) may have a delayed effect that is not captured
within the trial period. Fifth, while our analysis will ac-
count for the influence of some broader social and eco-
nomic factors on suicide rates, it may not account for
local changes (e.g., local changes in employment condi-
tions, natural disasters). To address this, we are docu-
menting significant local events and changes that may
influence suicide rates and that may help to understand
some regional variations in outcomes. Finally, given the
complexity of the model, it will not be possible to meas-
ure the potential synergistic interactions between inter-
ventions and relate this to magnitude of change in
suicide attempts at an area level or population level
within the trial sites.
Some of the strengths of this study are as follows: this
is the first suicide prevention trial of its kind in
Australia; the emphasis on the use of evidence-based
and multiple strategies to reach everyone in the commu-
nity, instead of targeting a specific strategy or problem
area. The results of this study are likely to have impact
for research and policy, internationally, given the
innovation of the LifeSpan model and the quality of the
data that we will acquire. Achieving implementation at-
scale and ensuring sustainability will be immensely
challenging. Yet, understanding implementation and sus-
tainability is key to the success of multilevel models such
as LifeSpan, and what is learned here is likely to have
implications for other highly complex problems. In
addition to measuring outcomes, we have commissioned
research to examine implementation and sustainability.
Given the scale and complexity of this work, the com-
prehensive findings of this research will be published
separately, and will also be referenced in discussing the
main outcomes of the LifeSpan trial.
Trial status
The selection process for trial sites was undertaken in
May and June 2016, and the selection process was com-
pleted in July 2016. The trial sites were randomized and
allocated in July 2016. Archival data for the evaluation
will be collected from 1 April 2012, and the last data col-
lection (indicating end of recruitment) will be acquired
in August 2021 (for suicide attempt) and April 2022 for
coronial data (based on current average time lags).
Appendix
The intervention components
Universal prevention strategies
1. Means’ restriction. A suicide audit report will be
provided to the site-lead agencies and suicide
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prevention collaboratives of each site during the
transition phase. This report will include the ana-
lysis of coronial, hospitalization, and ambulance
data to establish the demographic, socioeconomic,
and suicide means suicide risk profiles for each site.
It will also provide recommendations for tailored
means’ restrictions’ strategies against identified pri-
ority populations. The audit will include a detailed
appendix of evidence-based strategies to reduce ac-
cess to, or lethality of, means, which is intended as
a practical strategy to help sites decide what specific
means’ restriction strategies should be implemented
in their local region
2. Media guidelines. Local media representatives will
receive group-based face-to-face media training de-
livered by Mindframe Australia, aimed at reducing
dangerous reporting of suicide, and increasing re-
sponsible and respectful coverage of mental health
and suicide in the media. The target audience is
local journalists, suicide prevention multiagency
group members, organizational leaders, and local
leaders who might be asked to comment on suicide
by media and who are involved in community sup-
port after suicide. The training will be a 2-day, face-
to-face group program delivered in Year 1 of active
implementation at each site, with a half-day re-
fresher program delivered in Year 2
3. School-based suicide prevention. Year-9 high-school
students in all public, independent, and Catholic
high schools within the four sites will be offered an
evidence-based, universal suicide prevention pro-
gram designed to reduce stigma, increase help-
seeking behaviors and resilience, and reduce suicidal
ideation and behaviors. The Youth Aware of Mental
Health (YAM) program will be delivered over the 2-
year duration of the LifeSpan trial, meaning two con-
secutive cohorts of Year-9 students will receive
YAM. The YAM program was developed by re-
searchers and clinicians from the Karolinska Insti-
tute in Sweden and Cornell University in the USA.
Its primary aim is to raise awareness about suicide
risk and the factors that may protect against suicidal-
ity. YAM consists of five sessions delivered over a 3-
week period, and involve a mix of direct instruction,
reading material, visual information and interactive
workshops where young people are encouraged to
role-play skills within a supervised environment
4. Public awareness. Centrally developed resources
and materials with key messaging will be
disseminated to the general public within each of
the sites through a series of awareness-raising com-
munity events, in partnership with “R U OK” cam-
paign providers. The LifeSpan resources and
messages will be designed to engage the community
in suicide prevention, with a call to action; for ex-
ample, to complete gatekeeper training; sign up to
be a YAM helper; to reduce stigma; and to increase
identification and referral of individuals with sui-
cidal ideation or self-harming behaviors. Major
awareness-raising events will be held in September
in Year 1 and Year 2, during the national suicide
prevention awareness week
Selective strategies
5. Gatekeeper training. Question, Persuade, Refer
(QPR) training will be provided to all community
members in each of the four sites, to skill them in
being able to recognize and respond positively to
someone exhibiting suicide warning signs and
behaviors, including providing appropriate referral
information. This will be a brief (60-min) training
program, that individuals will sign up to, and then
they will be able to access their licence for up to 3
years, to refresh their gatekeeper skills. The digital
QPR program will be available at all times
throughout the active implementation period in
each site, and it will be advertised through the
public awareness strategy to increase uptake in the
community
6. Frontline responder training. First responders
(police, paramedics, and ED staff) will receive face-
to-face and online training to support individuals
with suicidal ideation or self-harming behaviors.
Training will be provided to first responders in each
of the four sites. Where training already exists, such
as the NSW Police Mental Health Intervention
Training (MHIT) program, support will be offered
to ensure that the program is meeting local needs.
The local implementation teams will identify key
decision-makers within each sector to work with
them in implementing training. The total number
of staff trained will vary by sector and site
7. Psychosocial treatments. A guide to evidence-based
psychological and pharmacological treatments for
the care of individuals with suicidal ideation and/or
behaviors will be provided to privately and publicly
employed psychologists, psychiatrists, and other
mental health professionals at each site. The Ad-
vanced Suicide Prevention Training program, de-
signed and facilitated by the Black Dog Institute,
will be provided for these professionals, to inform
appropriate assessment of suicidal ideation and/or
behaviors. This 6-h face-to-face group program
trains participants to undertake a suicide risk assess-
ment effectively; develop a collaborative safety plan;
implement a team approach to treatment planning;
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attempt; and respond to the needs of people be-
reaved by suicide. This training will be supple-
mented by information on local referral pathways,
delivered by a local subject-matter expert and pro-
gram champion. We aim to train 200 mental health
professionals at each of the four sites. The Collab-
orative Assessment and Management of Suicidality
(CAMS) framework will be implemented in relevant
healthcare settings in each site, with mental health
teams selected to participate according to their role
in providing treatment to people at risk of suicide.
CAMS is an evidence-based approach to managing
suicide risk [17, 18] and its implementation entails
structured training and implementation support
8. General practitioner (GP) capacity building and
training. General practitioners will receive training
and practice support to identify and refer
individuals with suicidal ideation or self-harming
behaviors. The Advanced Suicide Prevention Train-
ing program, designed and facilitated by the Black
Dog Institute, will be provided to general practi-
tioners. This 6-h face-to-face group-based program
trains participants to undertake a suicide risk assess-
ment effectively; develop a collaborative safety plan;
implement a team approach to treatment planning;
provide effective management following a suicide
attempt; and respond to the needs of people be-
reaved by suicide. In addition, general practices will
be provided with training by the Black Dog
Institute-developed “StepCare” program. StepCare
is designed to digitally screen patients for depres-
sion, anxiety, substance use, and suicidal thoughts
while they wait for their appointment. GPs will be
provided with detailed immediate feedback, verbal
scripts and recommendations for the patient via the
practice management software. Training for the
general practice staff in StepCare will come from a
trainer located within the Primary Health Network,
who will have received “train-the-trainer” from the
Black Dog Institute StepCare coordinator. We aim
to train and/or provide StepCare access to 50–60
general practitioners per site
Indicated strategies
9. Aftercare and crisis care following a suicide attempt.
The reform of care in the emergency department
(ED) and aftercare will be ongoing through the 2-
year implementation phase of LifeSpan. A set of
best-practice guidelines for effective crisis and after-
care has been developed [15] and will be
implemented in collaboration with EDs in each of
the four sites. The guidelines recommend that all
individuals presenting to the ED for a suicidal crisis
receive a comprehensive psychosocial assessment,
regardless of their perceived level of risk. This in-
cludes clear communication to the patient about
the role of the psychosocial assessment, with an
emphasis on the relational aspects of the assess-
ment. Each site will also commission an aftercare
support service that includes assertive outreach,
solution-focused counseling, support to adhere to
treatment, and where possible, continuity of contact
with the same staff member for up to 12 weeks
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